Promoting Localization of Core Processes
Enhancing Quality Control and Delivery Responsiveness

Photo by CAS

Photo by CAS

View original image

CAS, a leading domestic company specializing in weighing and measuring, is accelerating its efforts to strengthen competitiveness in the medical device business by establishing an in-house production base for blood pressure monitors, diversifying its supply chain, and expanding its product lineup. CAS recently announced that it has set up a production line and quality control infrastructure for blood pressure monitors at its Yangju factory and is moving forward with domestic production of upper arm automatic electronic blood pressure monitors.


This BP (Project) involves shifting from total OEM (original equipment manufacturing) imports, previously sourced from China and elsewhere, to direct domestic production. The project aims to enhance the value of the 'Made in Korea' brand and strengthen quality competitiveness.


To achieve perfect quality control and improve delivery response speed, the company plans to localize key parts and production processes and minimize risks stemming from global supply chain instability. In addition, CAS is working to secure a competitive cost structure by improving manufacturing efficiency.


The Yangju factory's production line is being established in accordance with medical device manufacturing guidelines. The site will feature a Class 8 assembly room with an air conditioning system, a Class 9 storage room for materials, wiring and cleaning rooms, and will implement Air Shower and Pass Box systems that separate workflows for personnel and logistics. These measures are expected to elevate quality standards throughout the entire medical device manufacturing process—from assembly and inspection to product sealing and packaging.


In accordance with Article 86 of the Foreign Trade Management Regulations, CAS plans to perform key processing tasks in Korea and increase the ratio of domestic manufacturing costs, thereby meeting legal standards for country of origin. The company also plans to pursue KGMP (Korean Good Manufacturing Practice) certification and ISO 13485:2016 certification, as well as product approval procedures within the year, after passing electrical and mechanical safety tests, electromagnetic compatibility (EMC) tests, and usability evaluations.


Notably, in addition to its current main model, CAS is considering establishing a domestic production system for various types of blood pressure monitors through technology transfer agreements with new partners. This approach is designed to reduce dependence on specific partners, disperse supply chain risks, and build a more flexible market response system.


Going forward, the company plans to develop a comprehensive product portfolio with a wide range of models and price points to increase its market share in the domestic healthcare market and strengthen its overall competitiveness in the healthcare business.


If CAS can leverage its long-standing technological expertise in precision weighing and measuring to enhance the reliability of domestically produced medical devices, the company is expected to demonstrate strong competitiveness not only in the domestic market but also in the global healthcare market in the future.


An official from the CAS Planning and Certification Office said, "Establishing an in-house production system for blood pressure monitors marks a significant milestone for CAS as it transitions from a traditional weighing and measuring specialist to a high-value-added healthcare device manufacturer. By leveraging the precise manufacturing infrastructure at the Yangju factory and the Planning and Certification Office’s thorough standards compliance, we aim to lay the foundation for a company-wide quality management system (QMS)."



The official added, "Through systematic schedule management, we will achieve a successful product launch and full-scale market supply in the second half of 2026."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing